Zenas BioPharma Inc ZBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $26.40
- Day Range
- $25.04–27.00
- 52-Week Range
- $13.50–44.60
- Bid/Ask
- $10.12 / $40.00
- Shares Outstanding
- 65.18M
- Market Cap
- $1.64B
- Volume/Avg
- 519,662 / 720,111
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,346.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 167
- Website
- https://www.zenasbio.com
Valuation
|
Metric
|
ZBIO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.45 |
Price/Sales | 1,346.32 |
Price/Cash Flow | — |
Price/Earnings
ZBIO
Financial Strength
|
Metric
|
ZBIO
|
|---|---|
Quick Ratio | 9.77 |
Current Ratio | 9.93 |
Interest Coverage | — |
Quick Ratio
ZBIO
Profitability
|
Metric
|
ZBIO
|
|---|---|
Return on Assets (Normalized) | −61.11% |
Return on Equity (Normalized) | −118.63% |
Return on Invested Capital (Normalized) | −81.80% |
Return on Assets
ZBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|JmT&PWD | LOCK|!<#cF | $123B | |||
| Moderna Inc
MRNA
| LOCK|H>$pWH | LOCK|MBD | $86B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|mXSQ^Dv | LOCK|$>YQ | $78B | |||
| argenx SE ADR
ARGX
| LOCK|<T!TL@ | LOCK|>#q | $50B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<C<!#mg | LOCK|>N | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|$YLGzr< | LOCK|@%VT! | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|NH@JmJ%X | LOCK|T!N#W | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|N<mh?bG | LOCK|lF@ | $22B | |||
| Incyte Corp
INCY
| LOCK|#cx!pD | LOCK|@< | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|m$x?^X | LOCK|HF | $14B |
United States